Immuneering to Participate in Jefferies 2021 London Healthcare Conference
November 10, 2021 06:50 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Third Quarter 2021 Financial Results and Recent Business Highlights
November 09, 2021 06:30 ET
|
Immuneering Corporation
Successfully completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering Reports Compelling Preclinical Data on IMM-1-104 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 11, 2021 06:50 ET
|
Immuneering Corporation
Preclinical Data Demonstrated Broad Antitumor Activity Across KRAS, NRAS and BRAF Mutant Tumor Models, Established Novel Mechanism of Action for its Dual MEK Inhibition and Showed Synergies with...
Immuneering to Present Key Preclinical Data Across Several Poster Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
October 01, 2021 06:50 ET
|
Immuneering Corporation
Preclinical Data Demonstrates Broad Antitumor Activity of IMM-1-104 Across RAS and RAF Mutant Tumors and Highlights Mechanistic Aspects of its Dual MEK Inhibition Company to Host Key Opinion Leader...
Immuneering Announces Inclusion in the Russell 2000® Index
September 20, 2021 16:10 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates
September 09, 2021 06:30 ET
|
Immuneering Corporation
Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024 Company expects to file IND for IMM-1-104 in Q1 2022 CAMBRIDGE, Mass.,...
Immuneering to Participate in September Investor Conferences
September 02, 2021 16:05 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
August 03, 2021 16:07 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Announces Pricing of Upsized Initial Public Offering
July 29, 2021 22:48 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 29, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates...
Immuneering Appoints Michael Bookman as General Counsel and Secretary
July 20, 2021 06:47 ET
|
Immuneering Corporation
CAMBRIDGE, Mass., July 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and neuroscience drug...